You can read the full October 2nd print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
Momentum for PBM reform was among the hot topics at a pharmacy roundtable conducted by Chain Drug Review during the NACDS Total Store Expo this summer in San Diego. Retailers, suppliers and industry advocates also discussed the prospects for standardization for prescription reimbursement, and for an expanded scope of practice for pharmacists, with remuneration for
On August 16, the Biden administration enacted the groundbreaking Inflation Reduction Act, a multifaceted law that addresses inflation, reduces the federal deficit and invests in long-term sustainability. This legislation has far-reaching implications for the American economy, prompting the pharmacy value chain to prepare for imminent disruptions. Pharmaceutical manufacturers will see direct impacts from the IRA,
By shifting the emphasis from treatment to prevention, the U.S. health care system can help people lead better lives, reduce health disparities and rein in massive expenditures that forestall investment in other urgent societal needs, including education, housing and environmental protection. As has often been noted here, this country spends far more on health care
If you happen to find yourself with a few idle days on your hands (How silly: Retailers seldom have a few extra days on their hands), you just might want to wander over to Des Moines, capital of Iowa, to examine how Hy-Vee, one of the truly stunning retailers this or any country has to
The erstwhile baseball all-star and philosopher Yogi Berra, renowned for malapropisms called “Yogisms,” had two famous quotes that could apply to the 2023 consumer health care world as it emerges from COVID: “The future ain’t what it used to be” and “You can observe a lot by just watching it.” The post-COVID future for consumer
